SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Kristen Jensen-Pergakes, John Tatlock, Karen A. Maegley, Indrawan J. McAlpine, Michele McTigue, Tao Xie, Christopher P. Dillon, Yuli Wang, Shinji Yamazaki, Noah Spiegel, Manli Shi, Amy Nemeth, Natalie Miller, Eleanore Hendrickson, Hieu Lam, John Sherrill, Chi-Yeh Chung, Elizabeth A. McMillan, Shannon Karlicek Bryant, Prakash Palde, John Braganza, Alexei Brooun, Ya-Li Deng, Vesta Goshtasbi, Susan E. Kephart, Robert A. Kumpf, Wei Liu, Ryan L. Patman, Eugene Rui, Stephanie Scales, Michelle Tran-Dube, Fen Wang, Martin Wythes and Thomas A. Paul

Mol Cancer Ther January 1 2022 (21) (1) 3-15; DOI: 10.1158/1535-7163.MCT-21-0620